Andrew Hollman Meyer - Jan 3, 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Business Officer
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 3, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 04:26 PM
Previous filing
Jun 10, 2021
Next filing
Jan 5, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.